The Middlemen on Trial: 10 PBM Lawsuits That Pulled Back the Curtain

There is a quiet, three-letter actor sitting between you and your medicine cabinet, and for years almost nobody knew its name. Pharmacy benefit managers, or PBMs, were invented to be helpful. They were supposed to be the smart shopper hired by your employer or your insurer to negotiate lower drug prices on your behalf. Instead, three of them, CVS Health's Caremark, Cigna's Express Scripts, and UnitedHealth's OptumRx, grew into gatekeepers that now process roughly 80% of the 6.6 billion prescriptions filled in the United States each year, with the top six controlling nearly 95%.

That kind of power attracts lawsuits. And the lawsuits, it turns out, are where the real story lives, because litigation is the one place where the contracts get unsealed, the internal emails get read aloud, and the math finally has to add up in front of a judge.

This report walks through ten of the most consequential PBM legal battles of the past decade. Each is structured as a case study, because each reveals a different mechanism in the same machine: the rebate trap, the DIR fee clawback, spread pricing, specialty-drug self-dealing, and the formulary exclusion lever that turns "we negotiate discounts" into "we inflate the sticker price and pocket the difference." The throughline is simple and ugly: a system engineered so that the higher a drug's list price climbs, the more money the middleman makes, and the more a diabetic, a cancer patient, or a small-town pharmacist pays.

Case Study 1The Insulin Trap — How a $21 Drug Became a $274 Drug

Insulin is the cleanest example of the rebate trap because the "before" picture is so stark. In 1999, the average list price of Eli Lilly's Humalog was about $21. By 2017 it was more than $274, an increase of over 1,200%. The molecule didn't get harder to make. Insulin's discoverers famously sold the patent for a dollar because they wanted it to be cheap forever.

So what happened? According to the FTC's administrative complaint against all three big PBMs and their affiliated group purchasing organizations, the middlemen ran a "chase-the-rebate" strategy. Here is the mechanic, in plain English:

• A PBM controls the formulary: the list of which drugs an insurance plan will cover, and on what tier.
• Getting onto that formulary is life-or-death for a drugmaker, because exclusion means losing access to millions of patients.
• So PBMs invited manufacturers to compete not on the lowest price, but on the biggest rebate: a payment kicked back to the PBM after the sale.
• A bigger rebate is easier to offer when you first jack up the list price and then "discount" off that inflated number.

The result is a perverse feedback loop: higher list price → bigger rebate → better formulary placement → even higher list price next year. The FTC alleges insulin list prices began their steep climb in 2012, precisely when PBMs started building exclusionary formularies. Novo Nordisk's NovoLog U-100 more than doubled from $122.59 in 2012 to $289.36 in 2018.

The messy reality behind the scenes. Net prices, what manufacturers actually collected after rebates, barely moved. Novo Nordisk reported NovoLog's list price rose 353% from 2001 to 2016 while the net price rose just 36%. That gap is the trap. The patients who got crushed were the ones whose out-of-pocket costs were tied to the list price: the uninsured, the underinsured, and anyone in a high-deductible plan paying coinsurance off a number everyone in the supply chain knew was fiction.

The human impact. This is where storytelling stops being a metaphor. An estimated 1.3 million insulin users, roughly 16.5% of Americans on insulin, reported rationing the drug because of cost. Among insulin users under 65, one in five reported rationing. Skipping doses to save money is not a budgeting choice; it is a medical event, and for some patients it has been fatal.

Where it stands. This case has become a constitutional knife fight. The PBMs sued the FTC, challenged the agency's in-house court, and got the proceeding temporarily stayed in 2025 amid the removal of FTC commissioners. On February 4, 2026, the FTC reached a landmark settlement with Express Scripts alone: no fine, no admission of wrongdoing, but a sweeping consent order requiring it to stop preferring high-list-price drugs over identical low-list-price versions, base patient cost-sharing on net price, move to cost-plus pharmacy reimbursement, and even reshore its rebate GPO, Ascent, from Switzerland. The agency estimates up to $7 billion in patient savings over ten years. The cases against Caremark and OptumRx continue.

Case Study 2The $290 Million Whistle — When the Math Was a Lie

If Case 1 is about list prices, this one is about a much quieter fraud: what the PBM told the government it paid pharmacies versus what it actually paid.

The whistleblower is the hero, and she is exactly the kind of person you want spotting a fraud. Sarah Behnke was the head actuary for Medicare Part D at Aetna. Her job was numbers. And the numbers didn't work. She noticed that Aetna, which used Caremark as its PBM, wasn't getting the same drug prices that Caremark's other clients got. Digging in, she alleged that Caremark was misreporting the prices it reimbursed pharmacies like Walgreens and Rite Aid for generic drugs dispensed to Medicare beneficiaries.

The messy reality behind the scenes. Medicare Part D requires PBMs to report accurate "pass-through" prices so the government reimburses the true cost of a drug. The court found Caremark instead caused health insurers to report false and inflated prices, so Medicare over-subsidized drug costs for years. After an eight-day bench trial in June 2025, Chief Judge Mitchell Goldberg found Caremark liable for $95 million in single damages.

Then came the part that made headlines. The False Claims Act mandates treble damages. On August 19, 2025, Judge Goldberg tripled the $95 million to $285 million, added $4.87 million in civil penalties at a rate of $9,500 per false claim, "near the top of the statutory range," and entered final judgment of $289,873,500.

The human impact. This one hit taxpayers and Medicare beneficiaries directly. When the reported price is inflated, the government overpays and seniors' cost-sharing climbs toward their out-of-pocket maximums faster. To put the scale in perspective: total False Claims Act settlements and judgments in the prior fiscal year were about $2.9 billion, meaning this single judgment approached 10% of the entire national total.

Where it stands. Caremark filed a notice of appeal to the Third Circuit on September 15, 2025. Notably, the court dismissed claims against parent CVS Health, finding it wasn't a party to the underlying contracts.

Case Study 3The Wall of "Standing" — Why J&J Employees Couldn't Win

Not every PBM case is a victory for the little guy. This one is a cautionary tale about how hard it is to hold anyone accountable, and it's arguably the most important case for employers to understand.

The premise was elegant. Under ERISA, an employer that sponsors a self-funded health plan is a fiduciary, legally obligated to manage the plan prudently and in participants' interest, the same way a 401(k) sponsor must. Ann Lewandowski, a J&J employee, filed a class action in February 2024 alleging that J&J breached that duty by mismanaging its prescription drug benefit and overpaying its PBM (Express Scripts), costing the plan and employees millions.

The poster-child example in the complaint: a generic multiple sclerosis drug the plan paid roughly $10,000 for a 90-day supply, when it could be bought for around $40. That is the kind of markup that makes a jury gasp, if it ever reaches a jury.

The messy reality behind the scenes. It never reached a jury. Twice. In January 2025, the court dismissed the case for lack of Article III standing: the legal requirement that a plaintiff show a concrete, traceable, redressable injury. The court called the alleged harm of higher premiums "speculative and hypothetical," resting "on nothing more than supposition." Even where Lewandowski paid higher out-of-pocket costs for specific drugs, the court ruled it couldn't redress the injury, because any refund would just flow back to the insurer. An amended complaint was dismissed again on November 26, 2025, with the court leaning on Navarro v. Wells Fargo to conclude there were "too many variables" linking PBM fees to what employees actually pay.

The human impact, and the systemic lesson. Here's the uncomfortable truth this case exposes. The system is so opaque, and the money flows are so layered, that even a plaintiff staring at a 250x markup couldn't prove she was personally, concretely harmed in a way a court would fix. The dysfunction is the defense. The same complexity PBMs profit from also shields the employers who hand them the keys.

Where it stands. Plaintiffs declined to amend a third time and filed a notice of appeal in January 2026. A parallel case, Stern v. JPMorgan Chase, is pending. The takeaway for any HR leader or CFO reading this: the courts just told you that you are a fiduciary, that these arrangements are litigable, and that your best defense is documented oversight of your PBM, not the hope that plaintiffs keep tripping over standing.

Case Study 4The Clawback — How DIR Fees Bled Independent Pharmacies Dry

Walk into a small-town pharmacy and ask the owner what keeps them up at night. The answer, for years, has been three letters: DIR.

"Direct and Indirect Remuneration" fees were born from a 2014 regulatory loophole. The rule let PBMs characterize certain price concessions as ones that "cannot reasonably be determined at the point of sale," meaning they could be collected after a prescription was filled. In practice, a pharmacy would dispense a drug, get paid, and then, weeks or months later, get a clawback based on opaque "performance" metrics it had no real ability to meet or predict.

The messy reality behind the scenes. The growth is the scandal. HHS itself admitted that pharmacy price concessions, including retroactive DIR fees, grew more than 45,000% between 2010 and 2017. The Osterhaus class action alleges DIR fees "grew more than 1,000 times larger" between 2010 and 2020, and that Caremark used its dominance to force independent pharmacies to "agree" to fees no rational business would accept, backed by arbitration clauses the suit calls unconscionable. The NCPA's CEO called it, memorably, "a mafia-style shakedown."

The arbitration track had already drawn blood: in 2021 an arbitrator awarded the AIDS Healthcare Foundation $23 million, finding Caremark breached the duty of good faith in its DIR practices, and a 2022 arbitration awarded $2.1 million plus $1.5 million in fees and interest over an "unconscionable" contract.

The human impact. Because the clawback is retroactive and unpredictable, a pharmacy literally cannot know whether dispensing a prescription will be profitable until long after the patient has walked out the door. A 2019 JAMA Internal Medicine study found one in eight pharmacies closed between 2009 and 2015, with independents in underserved areas hit hardest. And there's a cruel twist for patients: because the patient's copay at the counter is calculated before the clawback, beneficiaries often pay more out of pocket than the drug's true net cost. CMS finalized a rule in 2024 moving these concessions to the point of sale, a partial fix that pharmacies fought a decade to win.

Case Study 5The Handshake — Two PBMs Allegedly Agreed Not to Compete

This is the case that reads like an antitrust textbook, because the alleged conduct is the oldest sin in the book: competitors agreeing not to compete.

According to Michigan's 89-page complaint, in December 2019 Express Scripts gave Prime Therapeutics confidential information about the rates it paid independent pharmacies (allegedly lower than Prime's) and the per-fill fees it charged them (allegedly higher than Prime's). In exchange, Prime agreed to match those rates and fees and pay Express Scripts a cut every time it did.

The messy reality behind the scenes. The genius, and the alleged illegality, was scale. The arrangement effectively handed Express Scripts price control over Prime's 30 million beneficiaries, stacking them onto its existing 75 million for combined leverage over 105 million patients. The complaint alleges the resulting reimbursement rates were below what pharmacies paid to acquire the drugs, a structural guarantee of losses. Pharmacies could eat the loss or lose access to a network of 105 million patients, which for many meant going out of business entirely.

Layered on top: "preferred pharmacy networks" steering patients to affiliated stores, caps on refills at non-affiliated pharmacies, and aggressive "specialty drug" designations that forced the most profitable prescriptions into the PBMs' own pharmacies.

The human impact. When the only pharmacy in a rural county closes because it can't survive below-cost reimbursement, that's not an abstract market-share story. It's a "pharmacy desert," a community where the nearest place to fill a prescription is now an hour away. Michigan brought claims for restraint of trade, public nuisance, and unjust enrichment, alleging the conduct decreased healthcare access, raised costs, and wiped out small businesses statewide. This case is "specific to Michigan," the analysis notes, but "the conduct it alleges is nationwide."

Case Study 6The Web of Subsidiaries — Centene's Billion-Dollar Reckoning

Spread pricing is the simplest scam in the PBM playbook, and Centene's Medicaid saga is the most expensive demonstration of it.

Spread pricing works like this: the PBM bills the health plan (or in this case, the state Medicaid program) one price for a drug, pays the pharmacy a lower price, and silently keeps the "spread." The plan thinks it's paying the cost of the drug. It isn't.

The messy reality behind the scenes. Ohio Attorney General Dave Yost alleged that Centene used what he called a "web of subcontractors," including its PBM subsidiary Envolve and arrangements with CVS Caremark and OptumRx, to misrepresent pharmacy costs and overbill Ohio's Medicaid program. The structure was the disguise: layers of related entities made it nearly impossible for the state to see what the drugs actually cost.

In June 2021, Centene agreed to pay Ohio $88.3 million, at the time the largest state-AG PBM settlement in the country, and immediately settled with Mississippi for $55.5 million. Crucially, Centene admitted no fault.

The human impact and the scale. The tell was the reserve. Centene set aside $1.25 billion to resolve identical claims in other states. A company doesn't reserve $1.25 billion for a one-off. It then settled with a parade of states: Texas (~$166 million), Illinois ($56.7M), Kansas ($27.6M), New Hampshire ($21.1M), Arkansas ($15.2M), New Mexico ($13.7M), California ($215 million), Washington ($33M), and Massachusetts ($14M), among others. This is Medicaid money, funds meant to provide care for low-income families, quietly skimmed through a pricing structure designed to be unreadable.

Case Study 7The Discount That Never Arrived — Ohio v. OptumRx

If Centene shows spread pricing at the Medicaid level, OptumRx shows the related sleight-of-hand: promised savings that simply never get passed along.

The messy reality behind the scenes. Ohio's contract with OptumRx required the PBM to pass discounts on to the state when generic drug prices fell. According to AG Yost, between 2015 and 2018 OptumRx failed to do so, overcharging the state's Bureau of Workers' Compensation by more than $15.8 million. The case grew directly out of Ohio's broader PBM investigation, the same probe that found PBMs were taking large spreads on Medicaid generics and led the state to terminate its Medicaid PBM contracts and force a transparent pass-through model.

OptumRx confirmed a $15 million settlement in October 2022, and in a detail that captures the industry's reflexive opacity, the company publicly denied the deal two days after the state announced it, before confirming it.

The human impact. Workers' compensation exists to make injured workers whole. When the middleman pockets discounts that were contractually owed to the public, the cost lands on a state fund that exists to help people who got hurt on the job. Ohio's response became a national template: kill spread pricing, demand transparent pass-through, ban gag clauses, and let third-party auditors actually see the numbers.

Case Study 8The Phantom Prescriptions — CVS Omnicare's $949 Million Bill

This case isn't about pricing. It's about a CVS-owned pharmacy operation allegedly billing the government for prescriptions that didn't legally exist. It earns its place on this list because it shows the same pattern: a vertically integrated giant treating fraud penalties as a cost of doing business, and a judge refusing to let it.

The messy reality behind the scenes. Omnicare, the largest long-term care pharmacy in the U.S. (acquired by CVS in 2015), was accused of dispensing drugs to elderly and disabled residents of assisted-living facilities, group homes, and other settings on the basis of stale or invalid prescriptions, refilling drugs for over a year without a valid new script. The government joined the whistleblower's suit in 2019. In April 2025, a unanimous jury found Omnicare liable for 3,342,032 false claims between 2010 and 2018, with $135.6 million in damages.

In July 2025, Judge Colleen McMahon did the math. Treble damages brought the figure to $406.8 million, and she added a $542 million penalty for what she called "very big fraud," holding CVS jointly liable for $164.8 million for failing to stop the conduct after acquiring Omnicare, a total of $948.8 million. McMahon noted that applying the FCA's penalty "to the letter" would have produced an "astronomical" $26.9 billion floor, so CVS, in her words, was "getting off relatively easy."

The human impact. CVS's defense was telling: "There was no claim in this case that any patient paid for a medication they shouldn't have or that any patient was harmed." Set aside the legal merits: the framing reveals the worldview. Dispensing powerful drugs to vulnerable nursing-home residents without valid, current prescriptions is a patient-safety problem whether or not a bill landed on a patient's doorstep. CVS plans to appeal, arguing the penalty is an unconstitutionally excessive fine.

Case Study 9The Rebate Wall — How EpiPen Hit $600 With PBM Help

The EpiPen story is usually told as a tale of one villain: Mylan and its CEO. But the litigation revealed PBMs as essential co-architects of the price spike, through a tactic called the rebate wall.

The messy reality behind the scenes. A "rebate wall" works by using the size of a rebate to lock out competitors. The class plaintiffs alleged Mylan raised the EpiPen list price from roughly $100 to $600, a 500%+ increase, and used the fat margins to offer PBMs large rebates conditioned on excluding rival auto-injectors like Auvi-Q and Adrenaclick from formularies. A competitor selling a cheaper product literally couldn't match the rebate, because it didn't have an inflated list price to discount from. So the cheaper drug got walled off the formulary, and patients never saw it.

This is the rebate trap from Case 1, weaponized for exclusion rather than just inflation. It's why the FTC's later complaint warned that an insulin ruling could "materially impact the PBM business model as to other drugs as well," because the same lever moves epinephrine, inhalers, and dozens of other categories.

The human impact and the mixed legal record. The numbers are real. Mylan paid $465 million in 2017 to settle federal claims it misclassified EpiPen as a generic to dodge Medicaid rebates, and Pfizer (a manufacturing partner) settled related class claims for $345 million. As recently as April 2026, North Carolina recovered $11 million from Mylan, with the AG stating Mylan paid PBMs "to keep generics off preferred drug lists."

The honest counterpoint. Not every court bought the rebate-wall theory. In a separate suit by competitor Sanofi, a Kansas federal court granted summary judgment for Mylan in 2020, concluding the rebates were actually pro-competitive: that PBMs used exclusive placement to stimulate competition and drive net prices down, and that Sanofi could and did compete for the same business. This split is important and worth sitting with: rebate walls are genuinely contested terrain, and the same fact pattern can read as "exclusionary scheme" or "hard bargaining" depending on the court. A child carrying a $600 EpiPen they could barely afford doesn't experience the difference, but an honest account has to name it.

Case Study 10The Hidden Hand in the Opioid Crisis, and the $7.3 Billion Markup

The final case study is really two stories that share a theme: PBMs operating "largely hidden from public scrutiny," in places no one was looking.

The opioid front. For years, the opioid litigation targeted manufacturers (Purdue), distributors (McKesson, Cardinal, AmerisourceBergen), and pharmacies (CVS, Walgreens). PBMs were the quiet party. Then states started naming them. Kentucky sued Express Scripts in September 2024, alleging it was "legally responsible for its role in causing, contributing to, and maintaining the opioid epidemic," that it colluded with manufacturers to boost opioid supply and utilization through misleading claims, and dispensed opioids through its own mail-order pharmacy. The complaint's framing is the point: Express Scripts' role was "largely hidden from public scrutiny." Similar PBM opioid suits have been filed by West Virginia, Los Angeles County, and others.

The specialty-generic front. The FTC's Second Interim Staff Report, released January 2025, pulled back the curtain on where the Big 3 quietly make their money now: specialty generic drugs routed through their own affiliated pharmacies. The findings are staggering:

• The Big 3 marked up numerous specialty generics by thousands of percent: 22% of analyzed commercial drugs were marked up more than 1,000% over acquisition cost.
• One example: a drug pharmacies bought for an average of $27 was priced for reimbursement at $2,709.
• These markups generated over $7.3 billion in dispensing revenue above estimated acquisition cost from 2017 to 2022, growing at a 42% compound annual rate.
• The Big 3 disproportionately steered the most profitable prescriptions to their own pharmacies: 72% of drugs marked up over $1,000 per script went through affiliated pharmacies.

The human impact. These aren't lifestyle drugs. The marked-up specialty generics treat cancer (the generic of Gleevec for leukemia), HIV, multiple sclerosis, organ-transplant rejection, and pulmonary hypertension. A patient fighting leukemia is, unknowingly, the revenue source. And the FTC's first report found nearly 30% of surveyed Americans rationed or skipped doses of prescribed medicine due to cost. The vertical integration is what makes it invisible: when the PBM, the insurer, and the pharmacy are the same company, "negotiating a discount" and "paying yourself" become the same transaction.

The Pattern Underneath All Ten

Lay the cases side by side and the same five levers appear again and again. They are not separate scandals; they are one business model viewed from different angles.

The reason these practices survived so long is the reason Case 3 (J&J) failed: opacity is the product. When the contracts are sealed, the entities are nested, the prices are reported inaccurately, and the fees arrive months later, no single victim can easily prove what was taken from them. The litigation matters precisely because discovery and trial are the only tools powerful enough to force the math into the open.

Where the Story Goes Next

The momentum has shifted, but the war isn't over. The Express Scripts FTC settlement is a genuine structural change: delinking compensation from list prices, cost-plus pharmacy reimbursement, and net-price-based cost-sharing are exactly the reforms advocates have demanded for a decade. But it carries no fine and no admission of wrongdoing, applies to one of three giants, and, analysts note, largely codifies changes Express Scripts was already making. The cases against Caremark and OptumRx grind on. Caremark is appealing its $290 million Medicare judgment. The J&J appeal will test whether employees can ever clear the standing wall. State AGs keep filing.

The honest assessment for anyone who works in benefits, sells in this market, or simply takes a prescription: the legal system has finally proven, repeatedly and on the record, that the middlemen's math doesn't add up. What it hasn't yet done is change the math for most patients. That gap, between courtroom vindication and the price at the pharmacy counter, is the next decade's story.

— Tess